Trametinib

Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma and glioma. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. It is taken by mouth. The most common side effects include rash, diarrhea, tiredness, peripheral edema (swelling, especially of ankles and feet), nausea and acneiform dermatitis (acne-like inflammation of the skin). When taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash. In May 2013, trametinib was approved as a single-agent in the United States for the treatment of people with V600E mutated metastatic melanoma. It was authorized for medical use in the European Union in June 2014. Trametinib, as monotherapy or in combination with dabrafenib, is indicated for the treatment of melanoma and glioma. Clinical trial data demonstrated that resistance to single-agent trametinib often occurs within 6 to 7 months.